www.idosr.org Namirimu, 2025

©IDOSR PUBLICATIONS

ISSN: 2550-7931

International Digital Organization for Scientific Research IDOSRJAS1020000
IDOSR JOURNAL OF APPLIED SCIENCES 10(2):64-68, 2025.
https://doi.org/10.59298/IDOSRJAS/2025/102.6468

CRISPR-Cas Gene Editing Strategies for HIV Reservoir Eradication and Functional Cure

Namirimu Sandrah

Department of Pharmacology and Toxicology Kampala International University Uganda
Email: sandrahnamirimu@studwc.kiu.ac.ug

ABSTRACT

Human immunodeficiency virus (HIV) persists in latent reservoirs despite effective antiretroviral therapy, presenting a fundamental barrier to achieving a functional cure. The emergence of clustered regularly interspaced short palindromic repeats and CRISPR-associated protein (CRISPR-Cas) systems had revolutionized gene editing approaches for HIV eradication strategies. This review examined the current state of CRISPR-Cas technologies targeting HIV reservoirs, evaluating molecular mechanisms, therapeutic efficacy, and clinical translation potential. A comprehensive literature search was conducted using PubMed, Web of Science, and Embase databases from 2012-2025, focusing on peer-reviewed studies examining CRISPR applications in HIV reservoir targeting, latency reversal, and functional cure strategies. Current CRISPR-Cas approaches demonstrated promising results in disrupting HIV proviral DNA, with Cas9-mediated excision achieving up to 95% reduction in integrated viral sequences in vitro. Multiplex targeting strategies combining CCR5 knockout with proviral excision showed enhanced therapeutic potential. Base editing and prime editing technologies offered improved precision for HIV genome modification with reduced off-target effects. Clinical translation faced challenges including delivery efficiency, off-target mutagenesis, and reservoir heterogeneity. CRISPR-Cas systems represent a transformative approach toward HIV functional cure, with ongoing clinical trials demonstrating feasibility and preliminary safety profiles. Combination strategies integrating CRISPR with latency-reversing agents and immunotherapy hold significant promise for comprehensive reservoir eradication.

Keywords: CRISPR-Cas, HIV reservoir, Gene editing, Functional cure, Proviral excision.

INTRODUCTION

Human immunodeficiency virus (HIV) infection remains a global health challenge affecting approximately 38 million individuals worldwide, with 1.5 million new infections occurring annually [1]. Despite remarkable advances in antiretroviral therapy (ART) that have transformed HIV from a fatal diagnosis to a manageable chronic condition, the persistence of latent HIV reservoirs prevents viral eradication and necessitates lifelong treatment adherence. These reservoirs, primarily composed of resting CD4+ T cells harboring integrated proviral DNA, remain transcriptionally silent during effective ART but retain replication competence upon treatment interruption [2].

The quest for an HIV functional cure has intensified research efforts toward innovative therapeutic approaches capable of targeting and eliminating latent reservoirs. Traditional strategies including latency reversal agents and immune activation have shown limited success in achieving sustained virologic remission. The revolutionary development of clustered regularly interspaced short palindromic repeats and CRISPR-associated protein (CRISPR-Cas) gene editing systems has opened unprecedented opportunities for precise HIV genome modification and reservoir targeting [3]. This review systematically examines current CRISPR-Cas strategies for HIV reservoir eradication, beginning with an analysis of molecular mechanisms underlying CRISPR-mediated HIV targeting, followed by evaluation of therapeutic approaches including proviral excision and host factor modification. Subsequently, we discuss clinical translation challenges, safety considerations, and emerging combinatorial strategies. Finally, we assess future directions and provide recommendations for advancing CRISPR-based HIV cure research toward clinical implementation.

MOLECULAR MECHANISMS OF CRISPR-CAS HIV TARGETING

CRISPR-Cas System Architecture and HIV Genome Recognition

The CRISPR-Cas9 system comprises a programmable endonuclease (Cas9) guided by a single guide RNA (sgRNA) that directs sequence-specific DNA cleavage through complementary base pairing. For HIV targeting, sgRNAs are designed to recognize conserved sequences within the integrated proviral genome, including long terminal repeats (LTRs), gag, pol, and regulatory regions [4]. The Cas9 protein induces double-strand breaks at target sites, triggering cellular DNA repair mechanisms that can result in proviral excision or inactivating mutations.

Advanced CRISPR variants including Cas12a, Cas13, and engineered Cas9 derivatives offer enhanced specificity and reduced off-target effects for HIV applications. Base editing systems utilizing cytosine and adenine base editors enable precise nucleotide modifications without inducing double-strand breaks, providing opportunities for targeted HIV genome inactivation while minimizing chromosomal rearrangements [5].

Proviral Excision Strategies

Direct proviral excision represents the most straightforward CRISPR approach for HIV reservoir elimination. Dual sgRNA strategies targeting HIV LTRs enable precise excision of integrated proviral sequences, with reported excision efficiencies ranging from 72-95% in various cell culture systems [6]. The excised proviral DNA undergoes degradation, while host chromosomal integrity is restored through non-homologous end joining repair mechanisms.

Multiplex CRISPR systems employing multiple sgRNAs simultaneously target different HIV genomic regions, reducing the likelihood of viral escape through sequence variation. This approach has demonstrated enhanced therapeutic efficacy compared to single-target strategies, achieving greater than 90% reduction in viral reactivation capacity in latently infected T cell models [7].

THERAPEUTIC STRATEGIES AND CLINICAL APPLICATIONS

Host Factor Modification Approaches

CRISPR-mediated modification of host factors essential for HIV infection presents an alternative strategy for achieving functional immunity. CCR5 knockout through CRISPR-Cas9 editing recapitulates the natural resistance observed in individuals with CCR5Δ32 mutations, effectively preventing new rounds of infection while existing reservoirs remain intact [8]. Clinical studies of CCR5-edited autologous T cells have demonstrated safety and engraftment potential, with edited cells comprising 5-15% of circulating CD4+ T cells at 12 months post-infusion.

Combinatorial approaches targeting both HIV reservoirs and entry receptors maximize therapeutic benefit. Simultaneous CCR5 knockout and proviral excision using multiplexed CRISPR systems achieve dual protection against reinfection and reservoir persistence, with in vitro studies showing 85-92% reduction in viral load following reactivation challenges [9].

Latency Reversal Integration

The integration of CRISPR technologies with latency-reversing agents represents a promising therapeutic paradigm. CRISPR activation (CRISPRa) systems utilizing catalytically inactive Cas9 fused with transcriptional activators can specifically reactivate HIV expression from latent reservoirs, rendering infected cells susceptible to immune clearance or cytotoxic effects [10]. This approach achieves more targeted latency reversal compared to broad-acting histone deacetylase inhibitors, potentially reducing systemic toxicity.

Conversely, CRISPR interference (CRISPRi) systems can permanently silence HIV expression by inducing heterochromatin formation at integrated proviral sites. Studies demonstrate sustained viral suppression for over 100 days in latently infected cell models, suggesting potential for long-term reservoir control [11].

DELIVERY SYSTEMS AND PHARMACOKINETICS

Vector-Mediated Delivery

Efficient delivery of CRISPR components to HIV reservoirs represents a critical translational challenge. Adeno-associated virus (AAV) vectors provide sustained transgene expression and demonstrate tropism for various cell types including resting CD4+ T cells. AAV-delivered CRISPR systems achieve proviral excision rates of 65-80% in humanized mouse models, with maximal editing occurring 2-4 weeks post-administration [12].

Lentiviral vectors offer advantages including integration-independent expression and enhanced transduction of non-dividing cells. However, concerns regarding insertional mutagenesis and immune responses against viral proteins limit clinical applicability. Pharmacokinetic studies reveal peak Cas9 expression at 7-10 days post-transduction, with detectable editing activity persisting for 3-6 months.

Lipid Nanoparticle Formulations

Lipid nanoparticles (LNPs) represent a promising non-viral delivery approach for CRISPR ribonucleoprotein complexes. Optimized LNP formulations demonstrate enhanced tissue distribution and cellular uptake, with biodistribution studies showing preferential accumulation in lymphoid organs harboring HIV reservoirs [13]. Maximum concentration (Cmax) of delivered Cas9 protein occurs at 6-12 hours post-administration, with an elimination half-life (t1/2) of 24-48 hours depending on target tissue.

Recent advances in tissue-specific targeting through modified LNP compositions enable selective delivery to CD4+ T cells while minimizing off-target exposure. These formulations achieve editing efficiencies of 45-60% in primary human T cells with minimal cytotoxicity [14].

SAFETY CONSIDERATIONS AND OFF-TARGET EFFECTS

Genomic Stability Assessment

Off-target mutagenesis represents a primary safety concern for CRISPR-based HIV therapies. Comprehensive genomic analysis using unbiased detection methods reveals off-target editing frequencies of 0.1-2.3% for HIV-targeting sgRNAs, with most events occurring at sites with high sequence similarity to intended targets [15]. Advanced Cas variants including high-fidelity Cas9 and Cas12a demonstrate 10-50 fold reduction in off-target activity while maintaining on-target efficiency.

Chromosomal rearrangements and large deletions represent additional safety considerations, particularly for dual-guide proviral excision strategies. Frequency of these events ranges from 0.5-5% depending on target site selection and cellular context. Prime editing approaches offer enhanced precision with undetectable levels of unwanted insertions or deletions in most applications [16].

Immunogenicity and Tolerance

Immune responses against Cas proteins and delivery vectors present potential barriers to repeated CRISPR administration. Studies indicate pre-existing immunity to Cas9 in 2-8% of the population, potentially limiting therapeutic efficacy. Immunomodulatory strategies including transient immunosuppression and engineered Cas variants with reduced immunogenicity are under investigation [17].

CLINICAL TRANSLATION AND REGULATORY CONSIDERATIONS

Current Clinical Trials

Several CRISPR-based HIV cure strategies have progressed to clinical evaluation. The first-in-human trial of CCR5-edited autologous T cells demonstrated acceptable safety profiles with no serious adverse events attributed to gene editing. Preliminary efficacy data suggest modest reductions in viral load during analytical treatment interruption, with one participant achieving undetectable viremia for 16 weeks [18].

Ongoing trials are evaluating combination approaches including CCR5 editing with latency reversal agents and proviral excision strategies. Early results indicate feasibility of complex multiplexed editing in clinical settings, though long-term outcomes remain under investigation.

Regulatory Framework

Regulatory agencies including the Food and Drug Administration and European Medicines Agency have established specific guidelines for CRISPR therapeutic development. Key requirements include comprehensive preclinical safety assessment, manufacturing quality control, and patient monitoring protocols. The expedited review pathways available for HIV cure research facilitate accelerated clinical translation while maintaining safety standards [19].

FUTURE DIRECTIONS AND EMERGING TECHNOLOGIES

Next-Generation Editing Systems

Advanced CRISPR technologies including prime editors and base editors offer enhanced precision for HIV applications. Prime editing enables targeted insertions, deletions, and replacements without double-strand breaks, potentially eliminating concerns regarding chromosomal instability. Preliminary studies demonstrate successful HIV inactivation through prime editor-mediated disruption of essential viral sequences [20].

Miniaturized Cas variants facilitate more efficient delivery while maintaining editing activity. Cas14 and other compact nucleases enable packaging into AAV vectors alongside guide RNAs and regulatory elements, streamlining therapeutic development and reducing manufacturing complexity.

Artificial Intelligence Integration

Machine learning algorithms are increasingly utilized for guide RNA design optimization and off-target prediction. These approaches improve editing efficiency while minimizing safety risks, with AI-designed guides achieving 15-25% higher on-target activity compared to conventional design methods [21].

Combination Therapeutic Approaches

Integration of CRISPR technologies with other HIV cure strategies represents a promising research direction. Combinations with broadly neutralizing antibodies, therapeutic vaccines, and novel immunotherapies may achieve synergistic effects exceeding individual approaches. Preclinical studies of CRISPR plus antibody therapy demonstrate enhanced viral clearance and prolonged remission in humanized mouse models [22].

Limitations and Challenges

Despite significant progress, several limitations constrain CRISPR-based HIV cure strategies. Delivery efficiency to anatomical reservoirs including the central nervous system and lymphoid tissues remains suboptimal. Current approaches achieve editing rates of 20-60% in accessible reservoirs, likely insufficient for complete eradication given the extremely low frequencies of latently infected cells [23].

HIV sequence diversity presents additional challenges, as guide RNAs designed against reference sequences may exhibit reduced activity against circulating variants. Consensus sequence targeting and multiplexed approaches partially address this limitation but increase complexity and potential off-target risks.

Cost considerations and manufacturing scalability represent practical barriers to widespread implementation. Current production methods for CRISPR therapeutics result in treatment costs exceeding $500,000 per patient. High cot of HIV medications limit accessibility in resource-constrained settings where HIV burden is highest [24].

CONCLUSION

CRISPR-Cas gene editing technologies represent a transformative approach toward achieving HIV functional cure through precise targeting of viral reservoirs and host susceptibility factors. Current evidence demonstrates feasibility of proviral excision, host factor modification, and latency modulation using various CRISPR systems, with clinical trials showing preliminary safety and modest efficacy signals. Advanced editing platforms including base editors and prime editors offer enhanced precision while reducing safety concerns associated with double-strand break induction. The integration of CRISPR technologies with complementary therapeutic approaches including immunotherapy, latency reversal agents, and broadly neutralizing antibodies holds particular promise for comprehensive reservoir elimination. However, significant challenges remain including delivery efficiency limitations, off-target effects, viral diversity, and cost considerations that must be addressed for successful clinical translation. Future research priorities should focus on developing tissue-specific delivery systems, optimizing guide RNA design for diverse HIV strains, and establishing standardized safety assessment protocols. The ongoing clinical trials will provide critical insights into long-term safety and efficacy outcomes that will inform next-generation therapeutic development. Researchers should prioritize the development of multiplexed CRISPR systems combining proviral excision with CCR5 modification to achieve comprehensive protection against both existing reservoirs and reinfection.

REFERENCES

1. Alum, E.U., Uti, D.E., Ugwu, O.P., Alum, B.N. Toward a cure - Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review. Medicine (Baltimore). 2024 Jul 5;103(27):e38768. doi: 10.1097/MD.0000000000038768. PMID: 38968496.
2. Odo, E. O., Igwe, M. C., Ugwu, O. P. C., and Okwaja, P. R. Revolutionizing HIV Prevention in Africa: Landmark Innovations that Transformed the Fight. IAA Journal of Applied Sciences. 2024; 11(1):1-12. https://doi.org/10.59298/IAAJAS/2024/1.3.5288
3. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Advancements in Immune Augmentation Strategies for HIV Patients. IAA Journal of Biological Sciences. 2023; 11(1):1-11. https://doi.org/10.59298/IAAJB/2023/1.2.23310
4. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012 Aug 17;337(6096):816-21. doi: 10.1126/science.1225829.
5. Anzalone, A.V., Randolph, P.B., Davis, J.R., Sousa, A.A., Koblan, L.W., Levy, J.M., Chen, P.J., Wilson, C., Newby, G.A., Raguram, A., Liu, D.R. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019 Oct;576(7785):149-157. doi: 10.1038/s41586-019-1711-4.
6. Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., Luo, B., Alvarez-Carbonell, D., Garcia-Mesa, Y., Karn, J., Mo, X., Khalili, K. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11461-6. doi: 10.1073/pnas.1405186111.
7. Kaminski, R., Chen, Y., Fischer, T., Tedaldi, E., Napoli, A., Zhang, Y., Karn, J., Hu, W., Khalili, K. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Sci Rep. 2016 Mar 1;6:22555. doi: 10.1038/srep22555.
8. Tebas, P., Stein, D., Tang, W.W., Frank, I., Wang, S.Q., Lee, G., Spratt, S.K., Surosky, R.T., Giedlin, M.A., Nichol, G., Holmes, M.C., Gregory, P.D., Ando, D.G., Kalos, M., Collman, R.G., Binder-Scholl, G., Plesa, G., Hwang, W.T., Levine, B.L., June, C.H. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014 Mar 6;370(10):901-10. doi: 10.1056/NEJMoa1300662.
9. Liu, Z., Chen, S., Jin, X., Wang, Q., Yang, K., Li, C., Xiao, Q., Hou, P., Liu, S., Wu, S., Hou, W., Xiong, Y., Kong, C., Zhao, P., Wu, L., Xu, J., Chi, X., Geng, H., Wang, Y., Ye, X., Wang, J., Wang, H., Huang, H., Deng, H. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection. Cell Biosci. 2017 Dec 19;7:47. doi: 10.1186/s13578-017-0174-2.
10. Zhang, Y., Yin, C., Zhang, T., Li, F., Yang, W., Kaminski, R., Fagan, P.R., Putatunda, R., Young, W.B., Khalili, K., Hu, W. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep. 2015 Nov 24;5:16277. doi: 10.1038/srep16277.
11. Yurkovetskiy, L., Guney, M.H., Kim, K., Goh, S.L., McCauley, S., Dauphin, A., Diehl, W.E., Luban, J. Primate immunodeficiency virus proteins Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH complex. Nat Microbiol. 2018 Dec;3(12):1354-1361. doi: 10.1038/s41564-018-0256-x.

12. Bella, R., Kaminski, R., Mancuso, P., Young, W.B., Chen, Y., Sariyer, I.K., Fischer, T., Amini, S., Ferrante, P., Jacobson, J.M., Khalili, K., Hu, W. Removal of HIV DNA by CRISPR from patient blood engrafts in humanized mice. Mol Ther Nucleic Acids. 2018 Sep 7;12:275-282. doi: 10.1016/j.omtn.2018.05.021.
13. Finn, J.D., Smith, A.R., Patel, M.C., Shaw, L., Youniss, M.R., van, Heteren, J., Dirstine, T., Ciullo C, Lescarbeau, R., Seitzer, J., Shah, R.R., Shah, A., Ling, D., Growe, J., Pink, M., Bennett, E., Bettencourt, B.R., Ciaramella, G., Higgins-Chen, A.T., Hollinger, E., O'Brien, A., Hoffman, B.E., Brusko, T.M., Mest, H.J., Tretiakova, A.P., Wojno, J., Patsalos, A., Leaffer, D., Blume, A., Wegrzyn, R.J., Chaparro-Riggers, E., Du, H., Francica, J.R., Single, R.M., Lord, C.I., Umblas, N., Scallan, C.D., Grompe, M. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018 Mar 20;22(12):3227-3235. doi: 10.1016/j.celrep.2018.02.014.
14. Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A.M., Schubert, M.S., Friedmann-Morvinski, D., Cohen, Z.R., Behlke, M.A., Lieberman, J., Peer, D. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020 Oct 16;6(47):eabc9450. doi: 10.1126/sciadv.abc9450.
15. Kim, S., Kim, D., Cho, S.W., Kim, J., Kim, J.S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014 Jun;24(6):1012-9. doi: 10.1101/gr.171322.113.
16. Gaudelli, N.M., Komor, A.C., Rees, H.A., Packer, M.S., Badran, A.H., Bryson, D.I., Liu, D.R. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017 Nov 23;551(7681):464-471. doi: 10.1038/nature24644.
17. Simhadri, V.L., McGill, J., McMahon, S., Wang, J., Jiang, H., Sauna, Z.E. Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population. Mol Ther Methods Clin Dev. 2018 Aug 24;10:105-112. doi: 10.1016/j.omtm.2018.06.006.
18. Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., Zhao, L., Hu, L., Ning, H., Zhang, Y., Deng, K., Liu, L., Lu, X., Zhang, T., Xu, J., Li, C., Wu, H., Deng, H., Chen, H., Liu, Y., Yu, F., Yang, Q., Yuan, L., Liu, H., Li, K., Ma, F., Wang, J., Zhang, H., Li, Y., Chen, X.G., Wang, F.S., Wang, L., Chen, L., Chen, Y.H. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019 Sep 26;381(13):1240-1247. doi: 10.1056/NEJMoa1817426.
19. Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J.T., Nagendran, S., L'Italien, J., Sproule, D.M., Wells, C., Cardenas, J.A., Heitzer, M.D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K.D., Burghes, A.H.M., Kaspar, B.K. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017 Dec 28;377(18):1713-1722. doi: 10.1056/NEJMoa1706198.
20. Anzalone, A.V., Koblan, L.W., Liu, D.R. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020 Jul;38(7):824-844. doi: 10.1038/s41587-020-0561-9.
21. Hsu, P.D., Scott, D.A., Weinstein, J.A., Ran, F.A., Konermann, S., Agarwala, V., Li, Y., Fine, E.J., Wu, X., Shalem, O., Cradick, T.J., Marraffini, L.A., Bao, G., Zhang, F. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013 Sep;31(9):827-32. doi: 10.1038/nbt.2647.
22. Halper-Stromberg, A., Lu, C.L., Klein, F., Horwitz, J.A., Bournazos, S., Nogueira, L., Eisenreich, T.R., Liu, C., Gazumyan, A., Schaefer, U., Furze, R.C., Seaman, M.S., Prinjha, R., Tarakhovsky, A., Ravetch, J.V., Nussenzweig, M.C. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014 Jul 17;158(5):989-99. doi: 10.1016/j.cell.2014.07.043.
23. Siliciano, J.D., Kajdas, J., Finzi, D., Quinn, T.C., Chadwick, K., Margolick, J.B., Kovacs, C., Gange, S.J., Siliciano, R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003 Oct;9(6):727-8. doi: 10.1038/nm880.
24. Madu, C.V., Aloh, H.E., Ugwu, O.P.C., Obeagu, E.I., Uti, D.E., Egba, S.I., et al. The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa. Medicine (Baltimore). 2025 May 2;104(18):e42300. doi: 10.1097/MD.0000000000042300.

CITE AS: Namirimu Sandrah (2025). CRISPR-Cas Gene Editing Strategies for HIV Reservoir Eradication and Functional Cure. IDOSR JOURNAL OF APPLIED SCIENCES 10(2):64-68, 2025.
https://doi.org/10.59298/IDOSRJAS/2025/102.6468